SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01827436

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Motor Outcomes and Neural Correlates of Asymmetrical Gait Training in Children With Acquired Hemiplegia

The purposes of this pilot research study are 1. To begin to test if two different types of physical therapy might have different results in children and adolescents who have had a prior stroke, and 2. To determine if either type of physical therapy causes changes in the brain signals that control leg muscles. All participants will receive physical therapy 3 times per week for 8 weeks. Half of the participants will receive typical physical therapy, such as walking practice, muscle strengthening, and balance training. Half of the participants will receive asymmetrical gait training physical therapy, which uses new technology to train each leg differently during walking practice. After enrolling, participants will be randomly assigned to the type of therapy. Measurements will be taken before, during, and after the 8 weeks of physical therapy. These include walking tests to measure symmetry, walking speed and daily step activity, and brain tests to measure the strength of the signals from the brain to the leg muscles. One blood test is also taken to identify if certain genetic factors affect how each child responds to the physical therapy.

NCT01827436 Stroke Hemiplegia
MeSH: Stroke Hemiplegia
HPO: Hemiplegia Spastic hemiparesis Stroke

2 Interventions

Name: Conventional physical therapy

Type: Behavioral

Conventional physical therapy

Name: Asymmetrical gait training

Type: Behavioral

Asymmetrical gait training


Primary Outcomes

Measure: Change in walking symmetry

Time: before and after 8 weeks of therapy

Secondary Outcomes

Measure: Change in walking speed

Time: before and after 8 weeks of therapy

Measure: Change in excitability of neural motor pathways

Time: before and after 8 weeks of therapy

Measure: Change in patient/parent satisfaction rating

Time: before and after 8 weeks of therapy

Measure: Change in community step activity

Time: before and after 8 weeks of therapy

Other Outcomes

Measure: Changes in walking ability and cortical excitability measures (detailed above)

Time: before and after a 4 week baseline phase; before and after a 4 week withdraw phase

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 V66M

We will also establish a genetic database to identify the presence or absence of two genetic variants [Apolipoprotein E (ApoE Є4) and val66met Brain-derived neurotropic factor (BDNF) polymorphisms] associated with decreased potential for neuroplasticity for planning future investigations. --- val66met ---



HPO Nodes


HPO:
Hemiplegia
Genes 36
HLA-DPA1 PAH ARX PTPN22 ADA2 SCN1A NOTCH3 SLC1A3 STAT4 ATP1A2 SLC1A3 IRAK1 KRAS ATP1A3 GNAQ COL4A1 DOCK8 CTC1 ADA2 CACNA1A SNORD118 COL4A2 SPP1 PRF1 TBC1D24 CTLA4 FGFR1 POLA1 SUOX PRTN3 HLA-DPB1 C1QA ATP1A2 CACNA1A GCDH C1R
Spastic hemiparesis
Genes 2
HMGCL PRNP
Stroke
Genes 165
NAGS GDF2 MPL VHL GTF2I CST3 FBN1 SON BAZ1B SLC2A10 MAT2A PRKAG2 TREX1 ND1 SNAP29 TRNH COL4A1 TRNS2 ACAD9 TRNS1 CRELD1 ACVRL1 DPM3 GUCY1A1 CPS1 ND4 GNAQ LMNA RFC2 FOXE3 APP SMAD4 TGFBR2 TPP2 COL4A1 TRNK TRNL1 PRNP GATA4 HBB MYH11 COX2 HTRA1 SLC19A2 ENG TGFB3 PCNT CCM2 PIGA MMUT TRNQ TRNQ MPL MPL GTF2IRD1 SMAD4 TRNS2 ND6 PMM2 MYH11 SMAD4 GYS1 PRKCH ANGPTL6 SCN5A XYLT2 HSD11B2 ACTG1 TRNS1 CBS LIMK1 APP MFAP5 GUCY1A1 DYRK1B MTHFR TRNV SH2B3 COX3 MYH11 ALOX5AP NOS3 ENG NR2F2 TRNL1 ADA2 COX1 SLC19A2 MYD88 GLA JAG1 MLXIPL TP53 TRNW CLIP2 TRNC KRAS TRNF TET2 NOTCH3 ADA2 ND1 NR3C1 GATA6 NPPA ELN RFT1 SMARCAL1 AGXT FLNA TRNW COX3 JAK2 CYP11B1 CYTB F2 SMAD3 APP ACTA2 TNXB OTC APP COL3A1 TET2 ZMPSTE24 PRKG1 MYLK ASS1 TBL2 COX2 WFS1 THPO ELN PIK3C2A CALR JAK2 ENG TGFBR3 TGFB2 ND5 TTR F5 ND6 MECP2 ELN GLA ACTB ACVRL1 COX1 MYBPC3 APP TREX1 ND5 CST3 KCNQ1 COL3A1 ABCC6 ZAP70 TRNF HTRA1 LOX XYLT1 STIM1 JAK2 TGFBR1